Last update: Jan. 28, 2021


High Risk for breastfeeding

Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.

Muscle-relaxant drug which is marketed in some countries and usually associated to acetaminophen.
Oral administration twice a day.

Since the last update we have not found any published data on its excretion in breast milk.

Seizures have been described in a 3-month-old infant on the third day the mother took 8 mg of thiocolchicoside daily (Havali 2019).

Convulsions have been reported in susceptible persons (Giavina 2009, De Riu 2001).
There is a warning on likely mutagenic effects with a prolonged use. European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection (EMA 2013).

It is a drug with very few bibliographic references.


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Thiocolchicoside in other languages or writings:


Thiocolchicoside belongs to this group or family:


Main tradenames from several countries containing Thiocolchicoside in its composition:


Variable Value Unit
Oral Bioavail. 25 %
Molecular weight 564 daltons
Protein Binding 13 %
VD 0,4 - 0,6 l/Kg
pKa 12,2 -
Tmax 0,5 - 1 hours
T1/2 1,5 - 7 hours


  1. Havali C, Gucuyener K, Gurkas E, Demir E. Temporary Seizure in an Infant Who Had Been Exposed to G-Amino Butyric Acid Receptor Antagonist Thiocolchicoside. Pediatr Emerg Care. 2019 May;35(5):e96-e97. Abstract
  2. AEMPS. Tiocolchicosido. Ficha técnica 2015 Full text (in our servers)
  3. EMA. La Agencia Europea de Medicamentos recomienda restringir el uso del tiocolchicósido por vía oral o inyectable. 2014 Full text (in our servers)
  4. EMA. Thiocolchicoside. Drug Summary. 2013 Full text (in our servers)
  5. EMA. European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection. 2013 Full text (in our servers)
  6. Giavina-Bianchi P, Giavina-Bianchi M, Tanno LK, Ensina LF, Motta AA, Kalil J. Epileptic seizure after treatment with thiocolchicoside. Ther Clin Risk Manag. 2009 Abstract
  7. De Riu PL, Rosati G, Sotgiu S, Sechi G. Epileptic seizures after treatment with thiocolchicoside. Epilepsia. 2001 Abstract
  8. Sandouk P, Chappey O, d'Yvoire MB, Scherrmann JM. Pharmacokinetics of thiocolchicoside in humans using a specific radioimmunoassay. Ther Drug Monit. 1995 Abstract
  9. Perucca E, Poitou P, Pifferi G. Comparative pharmacokinetics and bioavailability of two oral formulations of thiocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers. Eur J Drug Metab Pharmacokinet. 1995 Abstract
  10. Sandouk P, Bouvier d'Yvoire M, Chretien P, Tillement JP, Scherrmann JM. Single-dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers. Biopharm Drug Dispos. 1994 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by AELAMA from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM